Growth visibility still limited: Q3 performance indicates stabilization rather than a broad-based recovery. Revenue remained largely flat QoQ and declined YoY, with growth concentrated in manufacturing (+3.1% QoQ) due to rampup of previously paused deals, which management indicated is largely onetime. Growth drivers appear narrow as key verticals such as BFSI, ER&U and Lifesciences remain soft, and Americas weakness persists. Headwinds in manufacturing and life sciences which are expected to continue into Q4 & recovery is expected only from Q1/Q2 FY27, leading to a back-ended growth...